Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial

In patients with ER+/HER2- metastatic breast cancer and selected genomic alterations, this triplet combination was active and had an acceptable toxicity profile (NCT04053322).

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-09-23
DOI
https://doi.org/10.1158/1078-0432.ccr-24-4221
Citations
2
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial

Audrey Mailliez, Étienne Brain, Anthony Gonçalvès, Pablo Lemercier et al.
2 citations
Clinical Cancer Research
PARP inhibition in cancer therapy
2.09
article

Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial

Audrey Mailliez, Étienne Brain, Anthony Gonçalvès, Pablo Lemercier, François P. Duhoux, Clara Guyonneau, Séverine Guiu, Jean‐Sébastien Frenel, Thomas Bachelot, Camille Chakiba, Louise-Marie Chevalier, Florence Dalenc, Isabel Pimentel, Elsa Curtit, Fanny Derquin, Jérôme Lemonnier, Frédéric Bigot, Suzette Delaloge, Judith Balmañà, Olfa Derbel, Adrien Buisson, Jean-Luc Canon, Philippe Follana
article en
2 citations

Abstract

In patients with ER+/HER2- metastatic breast cancer and selected genomic alterations, this triplet combination was active and had an acceptable toxicity profile (NCT04053322).

Clinical Cancer ResearchVol. 31(22)
Hebron University (PS), Centre National de la Recherche Scientifique (FR), Cliniques Universitaires Saint-Luc (BE), Inserm (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Hôpital René Huguenin (FR), Hôpital Privé Jean Mermo (FR), Vall d'Hebron Hospital Universitari (ES), Institut Claudius Regaud (FR), Centre Oscar Lambret (FR), Institut Bergonié (FR), Arcagy Gineco (FR), Institut de Recherche en Cancérologie de Montpellier (FR), UniCancer Group (FR), Centre de Recherche en Cancérologie de Marseille (FR), Institut Paoli-Calmettes (FR), Centre Antoine Lacassagne (FR), Grand Charleroi Hospital (BE), Institut Regional du Cancer de Montpellier (FR), Institut Curie (FR)
Openalex Percentile: Top 10%
PARP inhibition in cancer therapy
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.